查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088419

細胞治療技術市場：按產品/服務、治療類型、生產流程、給藥方法、應用和最終用戶分類－全球市場預測（2026-2032 年）

Cell Therapy Technologies Market by Offering, Therapy Type, Manufacturing Process, Delivery Method, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，細胞治療技術市場將成長至 140.2 億美元，複合年成長率為 14.37%。

主要市場統計數據
基準年（2025 年） 54.7億美元
預計年份（2026年） 62.5億美元
預測年份（2032年） 140.2億美元
複合年成長率（） 14.37%

細胞治療技術市場簡介

細胞治療技術是自體和異體移植的基礎技術，包括CAR-T細胞療法、腫瘤浸潤淋巴細胞療法、自然殺手細胞療法、間質幹細胞應用、造血幹細胞產品以及誘導多功能細胞衍生計畫。此技術體系涵蓋細胞分離、活化、基因轉移或基因編輯、增殖、密封生物製程、冷凍保存、出貨前檢驗、可追溯性管理以及溫控物流。

一項將重塑細胞療法技術的變革性變革。

細胞治療技術的演進正從人工操作、開放式和特定設施的工作流程轉向封閉式、自動化和數位化可追溯的生產模式。這項轉變的驅動力在於降低污染風險、縮短自體治療中「血液採集到輸注」的時間、提高批次間的一致性以及惠及更多患者。模組化潔淨室、自動化細胞處理系統、一次性生物反應器、快速無菌檢測和整合品質分析正成為至關重要的競爭優勢。

人工智慧對細胞療法的累積影響

人工智慧 (AI) 正在細胞治療技術的整個生命週期中創造累積價值。在藥物發現和轉化研究中，AI 可輔助標靶選擇、抗原逃脫分析、構建體最佳化、生物標記發現和患者分層。在生產製造中，機器學習可以幫助預測培養性能、及早發現偏差、最佳化培養基和補料策略，並提供基於影像的細胞形態、活力和表現型評估。

細胞治療技術的關鍵區域考量

北美地區仍然是細胞治療技術領域的領先地區，這得益於其生物技術公司、大學附屬醫療中心、合約研發生產機構（CDMO）、創業投資資金以及美國食品藥物管理局（FDA）的「再生醫學先進療法」等項目的集中。美國是臨床開發和商業化的核心，而加拿大則擁有強大的轉化研究、醫院網路和細胞生產能力。

各戰略經濟區內主要群體的分析

東協正憑藉新加坡的製造地、泰國的醫療旅遊生態系統、馬來西亞的生技藥品基礎設施以及全部區域不斷擴展的臨床研究能力而日益重要。海灣合作理事會（GCC）優先發展精準醫療、癌症治療和本地生物製藥生產能力，而沙烏地阿拉伯、阿拉伯聯合大公國和卡達則投資建造先進醫院、基因組學計畫和專科治療中心。

主要細胞治療市場逐國分析

美國憑藉FDA監管的核准流程、充裕的創業投資、大規模大學附屬癌症中心以及強大的CDMO（合約開發和生產）能力，在細胞療法技術的商業化方面處於世界領先地位。加拿大則透過轉化研究、公共衛生評估和先進製造舉措與之互補。墨西哥正在加強臨床研究和跨境醫療合作，而巴西則是拉丁美洲在先進療法監管、癌症治療需求和國內科學研究能力方面最為突出的市場。

為行業領導者提供的實用建議

產業領導者應優先考慮封閉式自動化生產平台，以提高可重複性、降低對操作人員的依賴性並加速不同地點間的技術轉移。在自體療法領域，儘早建立可擴展的流程尤其重要，因為治療計劃、患者來源材料的差異性以及身分鏈管理都會對商業性可行性產生重大影響。

分析方法

本報告採用結構化的二級研究和市場情報分析調查方法編制。資訊來源包括來自美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA)、日本藥品和醫療器材管理局 (PMDA)、國家藥品監督管理局 (NMPA) 和各國衛生部門的公開監管資訊、臨床試驗註冊數據、同行評審的科學文獻、專利和監管申請審查、產品核可歷史以及來自成熟的細胞治療開發公司、同行評審的科學文獻、專利和監管申請審查、產品批准歷史以及來自成熟的細胞治療開發公司、生產技術

結論

隨著已通過核准療法、臨床開發平臺和生產平台的不斷成熟，細胞療法技術正成為下一代醫學的核心支柱。該市場的長期潛力取決於產業能否將複雜的生物學轉化為標準化、標準化且可擴展的營運模式，從而惠及更多患者，並涵蓋更廣泛的適應症。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：人工智慧（AI）的累積影響（2026 年）

第7章 細胞治療技術市場：依產品/服務分類

  • 消耗品
  • 裝置
    • 生物反應器
    • 細胞分析儀
  • 軟體服務
    • 資料管理
    • 品管

第8章 細胞療法技術市場：依治療類型分類

  • 異體細胞療法
    • 樹突狀細胞
    • 誘導性多功能細胞
    • 自然殺手細胞
  • 自體細胞療法
    • 造血幹細胞
    • 間質幹細胞
    • T細胞
  • 基因修飾細胞療法
    • CAR-T細胞療法
    • TCR（T細胞受體）療法

第9章：細胞治療技術市場：依製造流程分類

  • 細胞培養
    • 2D培養系統
    • 3D培養系統
  • 細胞增殖
    • 黏附培養
    • 懸浮培養
  • 細胞分離
    • 螢光活化細胞分選
    • 細胞的磁激活

第10章 細胞治療技術市場：依給藥途徑分類

  • 體內
  • 體內

第11章 細胞治療技術市場：依應用領域分類

  • 心血管疾病
    • 缺血性心臟疾病
    • 周邊動脈疾病
  • 肌肉骨骼疾病
    • 骨關節炎
    • 類風濕性關節炎
  • 神經退化性疾病
    • 阿茲海默症
    • 帕金森氏症
  • 腫瘤學
    • 血癌
    • 固體癌
      • 乳癌
      • 肺癌
      • 攝護腺癌

第12章 細胞治療技術市場：依最終用戶分類

  • 生物製藥公司
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究機構
    • 政府附屬研究機構
    • 大學和學術機構

第13章 細胞治療技術市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 細胞治療技術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 細胞療法技術市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）

第17章：公司簡介

  • Adaptimmune Limited
  • Allogene Therapeutics Inc.
  • Atara Biotherapeutics, Inc.
  • Bellicum Pharmaceuticals, Inc.
  • Bluebird Bio Inc.
  • Cellectis SA
  • Century Therapeutics, Inc.
  • Charles River Laboratories International, Inc.
  • ElevateBio LLC
  • Gamida Cell Ltd.
  • GE HealthCare Technologies Inc.
  • Gilead Sciences, Inc.
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Legend Biotech USA Inc.
  • Novartis AG
  • Sartorius AG
  • STEMCELL Technologies Inc.
  • Takara Bio Inc.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • Vericel Corporation
Product Code: MRR-034230D3E636

The Cell Therapy Technologies Market is projected to grow by USD 14.02 billion at a CAGR of 14.37% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.47 billion
Estimated Year [2026] USD 6.25 billion
Forecast Year [2032] USD 14.02 billion
CAGR (%) 14.37%

Cell Therapy Technologies Market Introduction

Cell therapy technologies are the enabling platforms behind autologous and allogeneic therapies, including CAR T-cell therapy, tumor-infiltrating lymphocytes, natural killer cell therapies, mesenchymal stromal cell applications, hematopoietic stem cell products, and induced pluripotent stem cell-derived programs. The technology stack spans cell isolation, activation, gene transfer or gene editing, expansion, closed-system bioprocessing, cryopreservation, release testing, chain-of-identity controls, and temperature-controlled logistics.

The sector has moved from scientific promise to regulated commercialization. The U.S. FDA approved the first CAR T-cell therapies in 2017, and regulators in the United States, Europe, Japan, China, and South Korea have since advanced multiple cell and gene therapy pathways. For industry leaders, the central market question is no longer whether cell therapy can deliver clinical value, but how manufacturing platforms, quality systems, and digital infrastructure can scale these therapies reliably, safely, and cost-effectively.

Transformative Shifts Reshaping Cell Therapy Technologies

The cell therapy technologies landscape is shifting from manual, open, and site-specific workflows toward closed, automated, and digitally traceable manufacturing. This transformation is being driven by the need to reduce contamination risk, shorten vein-to-vein time for autologous therapies, improve batch consistency, and support broader patient access. Modular cleanrooms, automated cell processing systems, single-use bioreactors, rapid sterility testing, and integrated quality analytics are becoming essential competitive differentiators.

Scientific innovation is also reshaping demand. Allogeneic cell therapy, iPSC-derived platforms, CRISPR-based engineering, non-viral delivery, and next-generation immune cell therapies are expanding the addressable treatment landscape beyond hematologic malignancies into solid tumors, autoimmune diseases, inflammatory disorders, and regenerative medicine. At the same time, regulators are raising expectations for comparability, potency assays, long-term follow-up, and post-market evidence, making process control and data integrity central to commercial success.

Cumulative Impact of Artificial Intelligence on Cell Therapy

Artificial intelligence is creating cumulative value across the cell therapy technology lifecycle. In discovery and translational research, AI supports target selection, antigen escape analysis, construct optimization, biomarker discovery, and patient stratification. In manufacturing, machine learning can help predict culture performance, detect deviations earlier, optimize media and feeding strategies, and support image-based assessment of cell morphology, viability, and phenotype.

The strongest near-term impact is expected in quality control, release analytics, scheduling, and supply chain orchestration, where AI can reduce manual review burdens and improve decision speed. However, adoption must remain aligned with GxP expectations, validated datasets, cybersecurity controls, audit trails, and human oversight. Companies that treat AI as a governed quality and productivity layer rather than an isolated software tool will be better positioned to improve scalability without compromising patient safety.

Key Regional Insights for Cell Therapy Technologies

North America remains a leading region for cell therapy technologies due to its concentration of biotechnology companies, academic medical centers, contract development and manufacturing organizations, venture funding, and FDA programs such as Regenerative Medicine Advanced Therapy designation. The United States anchors clinical development and commercialization, while Canada contributes strong translational research, hospital networks, and cell manufacturing capabilities.

Europe benefits from the European Medicines Agency framework for advanced therapy medicinal products, strong public research systems, and established manufacturing hubs in Germany, France, Italy, Spain, and the United Kingdom. Asia-Pacific is expanding rapidly as Japan applies regenerative medicine-specific regulatory pathways, China scales domestic cell therapy trials and manufacturing, South Korea invests in advanced biopharmaceutical infrastructure, and Australia and Singapore strengthen clinical and process development ecosystems.

Latin America is emerging through Brazil and Mexico, where regulatory modernization, oncology demand, and partnerships with global developers are increasing visibility, although reimbursement and cold-chain constraints remain material. The Middle East, led by Gulf investment in advanced healthcare infrastructure, is building specialist centers and regional biomanufacturing ambitions. Africa remains earlier in adoption, but South Africa, Egypt, and selected academic networks are developing capacity through clinical collaborations, workforce training, and improved biobanking and laboratory infrastructure.

Key Group Insights Across Strategic Economic Blocs

ASEAN is gaining relevance through Singapore's biomanufacturing base, Thailand's medical tourism ecosystem, Malaysia's biologics infrastructure, and expanding clinical research capabilities across the region. The GCC is prioritizing precision medicine, oncology care, and local biopharmaceutical capacity, with Saudi Arabia, the United Arab Emirates, and Qatar investing in advanced hospitals, genomic programs, and specialist treatment centers.

The European Union provides one of the world's most structured regulatory environments for advanced therapy medicinal products, creating opportunities for harmonized development while still requiring careful navigation of country-level reimbursement and hospital adoption. BRICS countries offer scale, patient diversity, and growing domestic innovation, particularly in China, India, Brazil, and South Africa, but they also present heterogeneous regulatory, pricing, and infrastructure conditions.

G7 markets remain central to premium innovation, intellectual property generation, clinical evidence development, and early commercial uptake. NATO is not a healthcare trade bloc, but many NATO members overlap with major biopharmaceutical markets, making the alliance relevant to supply chain resilience, biosecurity coordination, critical raw material access, and continuity planning for advanced therapy manufacturing networks.

Key Country Insights for Leading Cell Therapy Markets

The United States leads global cell therapy technology commercialization through FDA-regulated approvals, deep venture capital, large academic cancer centers, and strong CDMO capacity. Canada complements this with translational research, public healthcare evaluation, and advanced manufacturing initiatives. Mexico is strengthening clinical research and cross-border healthcare links, while Brazil is Latin America's most visible market for advanced therapy regulation, oncology demand, and domestic scientific capacity.

In Europe, the United Kingdom remains influential through the MHRA, NHS-linked evidence generation, and the Cell and Gene Therapy Catapult. Germany combines engineering strength, hospital adoption, and bioprocessing expertise, while France supports advanced therapies through national research institutions and public-private initiatives. Italy and Spain contribute major clinical centers and ATMP manufacturing experience, and Russia maintains scientific capabilities despite market access and geopolitical constraints.

Across Asia-Pacific, China is scaling cell therapy research, clinical trials, and domestic manufacturing under evolving NMPA oversight. India is building affordability-focused innovation and hospital-based capacity, supported by a large patient base and growing biotechnology sector. Japan has a distinctive regenerative medicine framework and strong iPSC science, Australia offers high-quality clinical trial infrastructure, and South Korea combines government support, biomanufacturing strength, and an active cell and gene therapy developer base.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize closed and automated manufacturing platforms that improve reproducibility, reduce operator dependency, and enable faster technology transfer across sites. Building scalable processes early is critical, especially for autologous therapies where scheduling, patient material variability, and chain-of-identity controls can determine commercial viability.

Companies should invest in robust potency assays, rapid microbiology, digital batch records, and data architectures that connect development, manufacturing, quality, and clinical outcomes. Partnerships with hospitals, logistics providers, CDMOs, and regulators can reduce execution risk. Leaders should also diversify suppliers for critical reagents, viral vectors, media, single-use consumables, and cryogenic logistics to improve resilience and reduce bottlenecks.

Research Methodology

This executive summary is developed using a structured secondary and market-intelligence methodology. Inputs include publicly available regulatory information from agencies such as the FDA, EMA, PMDA, NMPA, and national health authorities; clinical trial registries; peer-reviewed scientific literature; patent and regulatory filing reviews; product approval histories; and industry announcements from established cell therapy developers, technology vendors, and CDMOs.

Insights are triangulated across regulatory evidence, clinical development activity, manufacturing trends, regional healthcare infrastructure, and commercialization signals. The analysis emphasizes verified and observable market drivers rather than unsupported projections, with a focus on technology adoption, quality requirements, regional readiness, and strategic implications for stakeholders across the cell therapy technologies value chain.

Conclusion

Cell therapy technologies are becoming a core pillar of next-generation medicine as approved therapies, clinical pipelines, and manufacturing platforms continue to mature. The market's long-term potential depends on the industry's ability to convert complex biology into standardized, compliant, and scalable operations that can serve more patients across more indications.

The strongest opportunities will accrue to organizations that integrate automation, analytics, AI-enabled decision support, regulatory readiness, and resilient supply chains. As regional ecosystems expand and global competition intensifies, cell therapy technology leaders that combine scientific excellence with manufacturing discipline will be best positioned to shape the future of advanced therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cell Therapy Technologies Market, by Offering

  • 7.1. Consumables
  • 7.2. Equipment
    • 7.2.1. Bioreactors
    • 7.2.2. Cell Analyzers
  • 7.3. Software & Services
    • 7.3.1. Data Management
    • 7.3.2. Quality Control

8. Cell Therapy Technologies Market, by Therapy Type

  • 8.1. Allogeneic Cell Therapy
    • 8.1.1. Dendritic Cells
    • 8.1.2. Induced Pluripotent Stem Cells
    • 8.1.3. Natural Killer Cells
  • 8.2. Autologous Cell Therapy
    • 8.2.1. Hematopoietic Stem Cells
    • 8.2.2. Mesenchymal Stem Cells
    • 8.2.3. T-Cells
  • 8.3. Gene-Modified Cell Therapy
    • 8.3.1. CAR-T Cell Therapy
    • 8.3.2. TCR (T-Cell Receptor) Therapy

9. Cell Therapy Technologies Market, by Manufacturing Process

  • 9.1. Cell Culture
    • 9.1.1. 2D Culture Systems
    • 9.1.2. 3D Culture Systems
  • 9.2. Cell Expansion
    • 9.2.1. Adherent Culture
    • 9.2.2. Suspension Culture
  • 9.3. Cell Separation
    • 9.3.1. Fluorescence-Activated Cell Sorting
    • 9.3.2. Magnetic-Activated Cell Sorting

10. Cell Therapy Technologies Market, by Delivery Method

  • 10.1. Ex vivo
  • 10.2. In vivo

11. Cell Therapy Technologies Market, by Application

  • 11.1. Cardiovascular Disease
    • 11.1.1. Ischemic Heart Disease
    • 11.1.2. Peripheral Artery Disease
  • 11.2. Musculoskeletal Disorders
    • 11.2.1. Osteoarthritis
    • 11.2.2. Rheumatoid Arthritis
  • 11.3. Neurodegenerative Diseases
    • 11.3.1. Alzheimer's Disease
    • 11.3.2. Parkinson's Disease
  • 11.4. Oncology
    • 11.4.1. Hematological Cancer
    • 11.4.2. Solid Tumors
      • 11.4.2.1. Breast Cancer
      • 11.4.2.2. Lung Cancer
      • 11.4.2.3. Prostate Cancer

12. Cell Therapy Technologies Market, by End User

  • 12.1. Biopharmaceutical Companies
  • 12.2. Hospitals
    • 12.2.1. Private Hospitals
    • 12.2.2. Public Hospitals
  • 12.3. Research Institutes
    • 12.3.1. Government Research Centers
    • 12.3.2. University Academics

13. Cell Therapy Technologies Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Cell Therapy Technologies Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell Therapy Technologies Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Adaptimmune Limited
  • 17.2. Allogene Therapeutics Inc.
  • 17.3. Atara Biotherapeutics, Inc.
  • 17.4. Bellicum Pharmaceuticals, Inc.
  • 17.5. Bluebird Bio Inc.
  • 17.6. Cellectis SA
  • 17.7. Century Therapeutics, Inc.
  • 17.8. Charles River Laboratories International, Inc.
  • 17.9. ElevateBio LLC
  • 17.10. Gamida Cell Ltd.
  • 17.11. GE HealthCare Technologies Inc.
  • 17.12. Gilead Sciences, Inc.
  • 17.13. Iovance Biotherapeutics, Inc.
  • 17.14. Johnson & Johnson Services, Inc.
  • 17.15. Legend Biotech USA Inc.
  • 17.16. Novartis AG
  • 17.17. Sartorius AG
  • 17.18. STEMCELL Technologies Inc.
  • 17.19. Takara Bio Inc.
  • 17.20. Takeda Pharmaceutical Company Limited
  • 17.21. Thermo Fisher Scientific Inc.
  • 17.22. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL THERAPY TECHNOLOGIES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CELL THERAPY TECHNOLOGIES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CELL THERAPY TECHNOLOGIES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CELL THERAPY TECHNOLOGIES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CELL THERAPY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOREACTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOREACTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOREACTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL ANALYZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL ANALYZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL ANALYZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DATA MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DATA MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DATA MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL QUALITY CONTROL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL QUALITY CONTROL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DENDRITIC CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DENDRITIC CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DENDRITIC CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NATURAL KILLER CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NATURAL KILLER CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NATURAL KILLER CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOLOGOUS CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AUTOLOGOUS CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOLOGOUS CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEMATOPOIETIC STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEMATOPOIETIC STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HEMATOPOIETIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL T-CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL T-CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL T-CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE-MODIFIED CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENE-MODIFIED CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE-MODIFIED CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CAR-T CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CAR-T CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TCR (T-CELL RECEPTOR) THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TCR (T-CELL RECEPTOR) THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TCR (T-CELL RECEPTOR) THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELL CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL 2D CULTURE SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL 2D CULTURE SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL 2D CULTURE SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL 3D CULTURE SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL 3D CULTURE SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL 3D CULTURE SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELL EXPANSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL EXPANSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELL EXPANSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADHERENT CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ADHERENT CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADHERENT CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SUSPENSION CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SUSPENSION CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SUSPENSION CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL SEPARATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELL SEPARATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL SEPARATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL FLUORESCENCE-ACTIVATED CELL SORTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL FLUORESCENCE-ACTIVATED CELL SORTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL FLUORESCENCE-ACTIVATED CELL SORTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MAGNETIC-ACTIVATED CELL SORTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MAGNETIC-ACTIVATED CELL SORTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MAGNETIC-ACTIVATED CELL SORTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL EX VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL EX VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EX VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IN VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IN VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IN VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CARDIOVASCULAR DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIOVASCULAR DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CARDIOVASCULAR DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ISCHEMIC HEART DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ISCHEMIC HEART DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ISCHEMIC HEART DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PERIPHERAL ARTERY DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PERIPHERAL ARTERY DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PERIPHERAL ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MUSCULOSKELETAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MUSCULOSKELETAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MUSCULOSKELETAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HEMATOLOGICAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEMATOLOGICAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HEMATOLOGICAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL GOVERNMENT RESEARCH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL GOVERNMENT RESEARCH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL GOVERNMENT RESEARCH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL UNIVERSITY ACADEMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL UNIVERSITY ACADEMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL UNIVERSITY ACADEMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 310. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 311. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 312. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 314. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 316. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 317. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 319. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 320. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 321. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 323. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 324. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 325. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 326. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 327. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2032 (USD MILLION)
  • TABLE 328. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 329. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 330. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 331. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 332. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 333. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 334. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 335. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 336. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 337. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 338. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 340. EUROPEAN UNION CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 342. EUROPEAN UNION CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 343. EUROPEAN UNION CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. EUROPEAN UNION CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 345. EUROPEAN UNION CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2